Legal Status of Peptides in Different Countries
As of October 2026, how the US, UK, EU, Australia, New Zealand and Canada regulate peptide sale, possession, prescription and import. Regulators in several of these countries say 'research use only' labels don't make supply lawful.
How peptide rules differ by country
Whether a peptide is legal depends on where you are and what you're doing with it. Selling and possessing are often covered by different rules, and so are importing and prescribing. A compound can be lawful to hold in one country and an offence in the next. This page covers the countries where we could check the rules against regulator documents in October 2026. Where we couldn't verify a country's position, we say so rather than guess.
One theme runs through almost every section. As of October 2026, each national regulator covered in detail below has said, in its own words, that a "research use only" label doesn't change what a product legally is.
Legal categories you'll see
| Category | What it means | Example (as of October 2026) |
|---|---|---|
| Prescription-only medicine | Supply needs a prescription; in some countries possession does too | BPC-157 in Australia and New Zealand |
| Unapproved drug | No marketing approval, so selling it for human use breaks medicines law | BPC-157 and TB-500 in the US |
| Controlled drug | Covered by drug-control law with criminal penalties | Growth hormone (somatropin) is Class C in the UK |
| Banned in sport | Prohibited under the WADA Prohibited List, separate from criminal law | BPC-157, TB-500, GH secretagogues |
United States
No common research peptide is FDA-approved, and none is a federally controlled substance. That doesn't make them "legal to purchase" in the simple sense the old version of this page claimed. Under federal drug law (the FD&C Act), a product intended for human use without FDA approval is an unapproved new drug, and selling it across state lines is a violation.
FDA made its view of research-use labels explicit in 2026. Warning letters sent on March 31 and August 24, 2026 told peptide sellers that, despite "for research use only" and "not for human consumption" statements, their websites showed the products were drugs intended for human use. The August letters covered retatrutide and other GLP-1 compounds as well as SS-31 and PT-141. FDA also cited sellers offering bacteriostatic water and dosing calculators as evidence the products were meant to be injected. These letters were aimed at sellers. They don't address individual buyers.
| Compound | US status (as of October 2026) |
|---|---|
| BPC-157, TB-500 | Not approved. Removed from FDA's 503A Category 2 list in April 2026, but not on the list of substances pharmacies may compound, so still not lawfully compoundable under 503A |
| Ipamorelin, CJC-1295 | Not approved; in no 503A category after negative advisory votes in 2024 |
| Human growth hormone | Approved prescription drug, not a scheduled controlled substance. Distributing it, or possessing it with intent to distribute, outside an FDA-authorized medical use ordered by a physician is a federal crime carrying up to 5 years in prison (21 U.S.C. 333(e)) |
Compounding is the area to watch. FDA's Pharmacy Compounding Advisory Committee met on July 23-24, 2026 to consider seven peptides for the 503A bulks list; BPC-157 and TB-500 were among them. FDA's own briefing papers proposed adding none of them. Press reports say the committee voted in favor of six. Its advice isn't binding, and as of October 2026 FDA hasn't proposed a rule. The list in 21 CFR 216.23 still contains no peptides.
United Kingdom
The UK uses two separate laws. The Misuse of Drugs Act 1971 lists somatropin (growth hormone) and HCG as Class C controlled drugs. When we checked the schedule in October 2026, it didn't name BPC-157 or TB-500, nor the common GH secretagogues.
Most other questions fall under the Human Medicines Regulations 2012, and there the MHRA decides case by case whether a product is a medicine. In April 2026 the MHRA's Head of Borderlines told The Pharmacist that the agency disregards "research purposes" claims when they're used to avoid medicines rules. The same statement added that peptides sold for bodybuilding without medicinal claims would often not be considered medicines. A pharmacy-law specialist quoted in that article argued most of them still meet the legal definition of a medicine, so the question isn't settled.
Enforcement in 2026 has focused on manufacturing and supply. In May 2026 the MHRA's Criminal Enforcement Unit made its largest-ever seizure of unlicensed weight-loss medicines, about 12,000 doses, at a site it said was making retatrutide and peptide products. Two people were arrested under the Human Medicines Regulations. We couldn't find a current MHRA statement on personal importation of research peptides, so the earlier claim that small imports are "usually okay" has been removed.
European Union
Under EU law, every medicine must be authorised before it can be marketed, either centrally through the European Medicines Agency or by a national regulator. Enforcement and prescription rules are set by each member state. We didn't verify current national positions on research peptides in October 2026, so the earlier country notes (Germany "stricter", the Netherlands "more permissive") have been cut.
Australia
As of the October 2026 Poisons Standard, the main research peptides are Schedule 4 (prescription-only) substances:
- BPC-157 and TB-500
- CJC-1295, ipamorelin and the GHRPs
- IGF-1 and growth hormone
BPC-157 and TB-500 are also listed in Appendix D clause 5, as are CJC-1295 and ipamorelin. That clause covers poisons that must not be possessed without authority. Possession without a prescription can therefore be an offence under state and territory law. Compounded GLP-1 medicines have been banned since October 1, 2024.
On April 13, 2026 the TGA issued a safety alert on unapproved peptide products. It named BPC-157 and TB-500 among its examples, and it stated that "research use only" disclaimers don't make supply lawful or permit importation. Personal importers still need a prescription for prescription-only goods, and the TGA says unlabeled or code-only vials won't be released at the border. These peptides aren't legal to buy without a prescription in Australia.
New Zealand
Medsafe classified BPC-157 as a prescription medicine at its May 25, 2023 classification meeting, after a run of personal imports. In a consumer advisory dated May 21, 2026, Medsafe said many peptide products are prescription medicines under the Medicines Act 1981. It's unlawful to import or possess them without authorisation. The advisory also said "for research purposes only" wording "has no legal effect."
Canada
Health Canada's April 9, 2026 public advisory (RA-81874) says peptides in Canada are "generally regulated as prescription drugs" and that unauthorized drug products are illegal. Its list of seized products includes BPC-157 and TB-500. It says "For Research Use Only" labelling doesn't make a product legal, and that Health Canada is working with the Canada Border Services Agency to stop shipments.
The earlier version of this page put growth hormone in Schedule IV of the Controlled Drugs and Substances Act. When we checked the Act in October 2026, Schedule IV listed anabolic steroids but not somatropin, so that claim has been removed.
Asia, the Middle East and Latin America
We couldn't find current regulator documents for these regions that address research peptides directly. The earlier claims on this page (for example, that Mexican pharmacies sell peptides without a prescription) had no sources, so they've been removed.
Sport rules are a separate system
Anti-doping rules apply on top of national law, and a peptide that's legal to hold can still end a tested athlete's career. As of October 2026, WADA's 2026 Prohibited List places them like this, all banned at all times:
- BPC-157: S0 (non-approved substances), named on the list since 2022
- TB-500 and other thymosin beta-4 derivatives: S2.3
- Growth hormone and its fragments: S2.2.3
- GHRH analogues and GH secretagogues: S2.2.4
- IGF-1 and its analogues: S2.3
The 2027 list takes effect on January 1, 2027. For more, see where common peptides sit on the Prohibited List, how strict liability works for tested athletes and testing procedures and athlete-specific rules.
What the rules mean in practice
National medicines regulators enforce the rules on selling and advertising medicines. In 2026 their public actions have mostly targeted sellers and manufacturers, through warning letters in the US and raids and seizures elsewhere. Customs agencies enforce import rules at the border, often at a regulator's request. In Australia and New Zealand the law also reaches people who possess prescription-only peptides without authority.
The lawful route to a peptide medicine runs through a prescriber. Approved peptide drugs, semaglutide for example, are prescription medicines in every country covered here. For unapproved peptides there is usually no routine prescription route. UK law does allow an unlicensed medicine to be supplied for an individual patient's special clinical needs, but UK legal commentators note this isn't a general route for clinics to offer experimental peptides as wellness treatments. A research-use vial isn't equivalent to a prescription medicine in any of these systems.
What to watch next
- Whether FDA proposes a rule on the six peptides its advisers backed in July 2026, and the second advisory meeting planned before the end of February 2027
- The WADA 2027 Prohibited List, in force from January 1, 2027
- Further Poisons Standard updates in Australia and Medsafe classification decisions in New Zealand
This page is general information, not legal advice. Laws change, and enforcement varies within countries.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- FDA warning letter to Royal Peptides LLC on research-use-only peptides (FDA, August 24, 2026)
- FDA warning letter to Gram Peptides (FDA, March 31, 2026)
- 21 U.S.C. 333(e): prohibited distribution of human growth hormone (Cornell Legal Information Institute, accessed October 2026)
- FDA advisory committee reviews BPC-157, TB-500 and five other peptides for compounding (PepFinder, 2026)
- Misuse of Drugs Act 1971, Schedule 2 (legislation.gov.uk, accessed October 2026)
- Grey-market peptides: what pharmacists need to know, with MHRA comment (The Pharmacist, April 2026)
- Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines (MHRA, May 29, 2026)
- Peptides in aesthetics and wellness: regulatory and criminal risks (Legal 500, 2026)
- Authorisation of medicines (European Medicines Agency, accessed October 2026)
- Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026 (Federal Register of Legislation, Australia)
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products (TGA safety alert, April 13, 2026)
- Classification of unscheduled peptides, including BPC-157 (Medsafe Medicines Classification Committee paper)
- Consumer advisory: unapproved peptide products health warning (Medsafe, May 21, 2026)
- Think twice before injecting peptides bought online, advisory RA-81874 (Health Canada, April 9, 2026)
- Controlled Drugs and Substances Act, full text including Schedule IV (Justice Laws Website, Canada, accessed October 2026)
- World Anti-Doping Code: 2026 Prohibited List (WADA, 2025)